Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710881 | 0.80 | ALDH1A1 (0.41) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL5316195 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL264829 | 0.76 | — | — | |
| SCHEMBL264731 | 0.72 | ALDH1A1 (0.41) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL264599 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL12050480 | 0.71 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL238094 | 0.69 | ALDH1A1 (0.47) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL31135304 | 0.69 | ALDH1A1 (0.38) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL17181089 | 0.69 | ALDH1A1 (0.35) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL16978778 | 0.68 | ALDH1A1 (0.37) | ALDH1A1CYP2D6CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232110-A1 | CONJUGATE FOR TREATING MALARIA | STELLENBOSCH UNIVERSITY (ZA) | 2017-08-17 | — | — | US | disclosed |
| US-20170232110-A1 | CONJUGATE FOR TREATING MALARIA | STELLENBOSCH UNIVERSITY (ZA) | 2017-08-17 | — | — | US | disclosed |
| WO-2016024240-A1 | CONJUGATE FOR TREATING MALARIA | STELLENBOSCH UNIVERSITY (ZA) | 2016-02-18 | — | — | WO | disclosed |
| US-5977395-A | ALKYLATION | RHONE-POULENC CHIMIE (FR) | 1999-11-02 | — | — | US | disclosed |
| US-5637722-A | ALKYLATION OF NUCLEOPHILE WITH ALKYL PROPARGYL XANTHATE | RHONE-POULENC CHIMIE (FR) | 1997-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232110-A1 | CONJUGATE FOR TREATING MALARIA | CD4, NGLY1, PTMS | ALDH1A1 4512/4885CYP2D6 2243/4885CA12 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.